Everolimus in Anaplastic Thyroid Cancer: A Case Series
暂无分享,去创建一个
R. Tishler | P. Janne | J. Barletta | N. Chau | R. Haddad | J. Lorch | G. Hanna | D. Margalit | J. Schoenfeld | Matthew A. Nehs | G. Rabinowits | Julian Huang | A. Kacew | Ethan J Harris | Phillip Groden | Alec J Kacew
[1] T. Fukuhara,et al. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction , 2018, European Thyroid Journal.
[2] Stephanie L. Lee,et al. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study , 2018, Clinical Cancer Research.
[3] Yasuhiro Ito,et al. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma , 2017, Thyroid : official journal of the American Thyroid Association.
[4] K. Nakano,et al. Lenvatinib for Anaplastic Thyroid Cancer , 2017, Front. Oncol..
[5] Thomas C. Lee,et al. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer , 2016, Clinical Cancer Research.
[6] Jiang Wang,et al. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] C. Sander,et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.
[8] Kristen A Marten,et al. Use of vemurafenib in anaplastic thyroid carcinoma: a case report , 2015, Cancer biology & therapy.
[9] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[10] P. Bycott,et al. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses , 2014, Cancer Chemotherapy and Pharmacology.
[11] Nikhil Wagle,et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.
[12] R. Paschke,et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.
[13] I. Matos,et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). , 2017, European journal of endocrinology.
[14] M. McMahon,et al. Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis , 2014, Molecular Cancer Research.
[15] H. G. Kim,et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] V. D. Di Crescenzo,et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.
[17] M. Merlano,et al. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer , 2013, OncoTargets and therapy.
[18] J. Wright,et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. , 2013, Thyroid : official journal of the American Thyroid Association.
[19] J. Glaspy,et al. BRAF V600E inhibition in anaplastic thyroid cancer. , 2013, The New England journal of medicine.
[20] Andrea K. Kukla,et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.
[21] A. Miyauchi,et al. Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients , 2012, World Journal of Surgery.
[22] S. Remick,et al. Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment , 2011, Journal of oncology.
[23] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[24] Michelle D. Williams,et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. , 2010, The Journal of clinical endocrinology and metabolism.
[25] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[26] S. Asa,et al. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression , 1993, Endocrine Pathology.
[27] D. Schoenfeld,et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.
[28] P. Wen,et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Claude-Alain H. Roten,et al. Theoretical and practical advances in genome halving , 2004 .